PMID- 27350545
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160908
LR  - 20220408
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 7
IP  - 3
DP  - 2016 Sep
TI  - Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the 
      Real-World Setting: A Systematic Literature Review.
PG  - 411-38
LID - 10.1007/s13300-016-0180-0 [doi]
AB  - INTRODUCTION: In clinical trials, liraglutide has proven to be an effective drug 
      for the treatment of type 2 diabetes mellitus (T2DM). The real-world 
      effectiveness of liraglutide has been investigated in numerous studies. The aim 
      of this systematic literature review is to collate evidence on the real-world 
      clinical effectiveness of liraglutide. METHODS: A review of publications from 
      Medline, EMBASE, the Cochrane Library, and conference proceedings was conducted 
      to identify observational studies that assessed the clinical effectiveness of 
      liraglutide in real-world clinical practice. This review was conducted according 
      to the National Institute of Health and Care Excellence (NICE) guidance. No 
      language or time limits were applied, except to the conference proceedings 
      (2013-2015). Endpoints for data extraction were decided a priori. Study quality 
      appraisal was done for full-text journal articles. RESULTS: Of 124 publications 
      included in the review, 43 were full-text articles. Liraglutide significantly 
      reduces glycated hemoglobin (HbA1c) within 6 months of initiating treatment (mean 
      change in HbA1c from baseline: -0.9% to -2.2%; HbA1c <7.0%: 29.5-65.0%). The NICE 
      composite endpoint (HbA1c reduction >/=1% and weight reduction >/=3%) was met in 
      16.9-47.0% of patients with liraglutide treatment. Liraglutide therapy led to a 
      mean change in absolute weight from baseline of -1.3 to -8.65 kg. Liraglutide 
      treatment was well tolerated in patients with T2DM. The rate of occurrence of 
      hypoglycemia with liraglutide monotherapy was </=0.8%. Hypoglycemia was more common 
      in patients taking antidiabetic medications (0.0-15.2%) together with 
      liraglutide. The beneficial glycemic and weight effect of liraglutide therapy in 
      patients with T2DM was maintained for at least 12 months. CONCLUSION: Evidence 
      from observational studies reflecting real-world clinical practice demonstrates 
      that liraglutide therapy improves glycemic control with a low risk of 
      hypoglycemia, and is associated with significant weight loss in patients with 
      T2DM. These observations are consistent with clinical trial findings. FUNDING: 
      Novo Nordisk A/S, Soborg, Denmark.
FAU - Ostawal, Amrita
AU  - Ostawal A
AD  - Pharmerit GmbH, Berlin, Germany.
FAU - Mocevic, Emina
AU  - Mocevic E
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Kragh, Nana
AU  - Kragh N
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Xu, Weiwei
AU  - Xu W
AD  - Pharmerit International, Rotterdam, The Netherlands. wxu@pharmerit.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160627
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5014786
OTO - NOTNLM
OT  - Effectiveness
OT  - HbA1c
OT  - Hypoglycemia
OT  - Liraglutide
OT  - Literature review
OT  - Real-world evidence
OT  - Safety
OT  - Type 2 diabetes
OT  - Weight
EDAT- 2016/06/29 06:00
MHDA- 2016/06/29 06:01
PMCR- 2016/06/27
CRDT- 2016/06/29 06:00
PHST- 2016/05/10 00:00 [received]
PHST- 2016/06/29 06:00 [entrez]
PHST- 2016/06/29 06:00 [pubmed]
PHST- 2016/06/29 06:01 [medline]
PHST- 2016/06/27 00:00 [pmc-release]
AID - 10.1007/s13300-016-0180-0 [pii]
AID - 180 [pii]
AID - 10.1007/s13300-016-0180-0 [doi]
PST - ppublish
SO  - Diabetes Ther. 2016 Sep;7(3):411-38. doi: 10.1007/s13300-016-0180-0. Epub 2016 
      Jun 27.